Zacks Investment Research | Aug 24, 2017 09:47PM ET
Global leader in the field of DNA sequencing and array-based technologies, Illumina, Inc. (NASDAQ:ILMN) along with Telegraph Hill Partners (“THP”) announced plans to set up an independent company Verogen, Inc. THP is a life science-focused venture capital and growth equity firm based in San Francisco. Verogen, headquartered in the San Diego area, will have rights to provide Illumina’s forensic sequencing technology to forensic customers, including criminal casework and other human and nonhuman forensic applications.
The independent company is expected to strengthen Illumina’s next-generation sequencing (NGS) business in the forensic genomics market. It will be the sole provider of the MiSeq FGx Forensic Genomics System, including the MiSeq FGx sequencer, ForenSeq DNA Signature Prep Kit and the ForenSeq Universal Analysis Software. It will also have the global commercial rights to these products.
The MiSeq FGx Forensic Genomics System is used in operational crime laboratories, private service labs and forensic research institutes worldwide. The company will also be offering other Illumina products to forensic labs to operationalize NGS in routine forensic genomics.
Illumina will continue to manufacture the MiSeq FGx Instrument and core sequencing consumables. Management believes that the MiSeq FGx Forensic Genomics System continues to lead the transition to NGS.
Genomics in forensic market will improve justice and public safety while removing the barriers to adopt NGS in crime laboratories. The companies are hopeful that Illumina’s NGS technology together with THP’s forensic experts will help Verogen provide long-term success to customers.
Kirk Malloy has been named CEO of Verogen, while Cydne Holt will serve as General Manager and Chief Scientific Officer.
According to a BCC research report, the major U.S. forensic products and services market will reach a worth of nearly $16.3 billion in 2018, at a CAGR of 7.8% in the period 2013 to 2018. Thus, the company clearly has bountiful opportunities in this space.
Illumina is striving to expand its NGS technology base. In line with this, Illumina had announced the launch of a solution under its noninvasive prenatal testing (NIPT) kit in Europe. The product VeriSeq NIPT solution is a CE-IVD marked next-generation sequencing (NGS)-based approach to NIPT.
Also, Illumina announced that its Extended RAS Panel, an FDA-approved next-generation sequencing (NGS) kit, meets the newly published guidelines for evaluation of colorectal cancer.
The company had also launched Bio-Rad Single-Cell Sequencing Solution, the first next-generation sequencing (NGS) workflow for single-cell analysis, in collaboration with Bio-Rad Laboratories, Inc. (NYSE:BIO) .
Over the last three months, Illumina has been trading above the broader Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.